Expert Interview
Examining the Topline Results from the CANYON Phase 2 Trial of Sevasemten in Becker Muscular Dystrophy
Ticker(s): EWTXInstitution: University of Buffalo
- Clinical Associate Professor of Neurology at the University of Buffalo.
- Research is focused on several studies that address illnesses such as Guillain-Barre syndrome, myasthenia gravis and polyneuropathy.
- Basic science research is focused on pathophysiology of inherited neuropathies, which are known collectively as Charcot-Marie-Tooth (CMT) disease, with the goal of better understanding the underlying cause or mechanisms of these diseases.
Describe your background and practice setting
Added By: ben_adminHow many patients with BMD do you manage?
Added By: ben_adminWhat are your takeaways from the Canyon study?
Added By: ben_adminWhat are your impressions of the mechanism of action of sevasemten targeting skeletal myosin and the data from the CANYON Phase II trial, including its relationship to the ARCH study?
How do you view the inclusion criteria, baseline characteristics, and potential imbalances between treated and placebo groups, as well as their impact on the trial outcomes?
Added By: slingshot_insightsWhat is your assessment of the safety profile, including adverse events and serious adverse events, and the clinical significance of the reductions in biomarkers and functional data trends?
Added By: slingshot_insightsHow optimistic are you about the GRAND CANYON trial design and potential outcomes, and how do you see sevasemten being used in different BMD populations if approved?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
